A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

Inclusion Criteria

• •1. Sign written informed consent;
• •2. Age ≥18 years;
• •3. Conforms to the NCP Critical and Critical Diagnostic Standards, namely "Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 6)". Comprehensive judgment based on epidemiological history, clinical manifestations and etiological examination;
• •4. The course of disease is within 14 days after the onset of illness;
• •5. Willing to collect nasopharyngeal or oropharyngeal swabs before administration.